Cholesterol–PEG comodified poly (N-butyl) cyanoacrylate nanoparticles for brain delivery: in vitro and in vivo evaluations

References

• Alyautdin RN, Petrov VE, Langer K, et al. (1997). Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 14:325–8
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Tezikov EB, Ramge P, et al. (1998). Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 15:67–74
   PubMed Web of Science ®Google Scholar
• Bhaskar S, Tian F, Stoeger T, et al. (2010). Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fiber Toxicol 7:1–25
   PubMed Web of Science ®Google Scholar
• Bhattacharyyaa SS, Paula S, Dea A, et al. (2011). Poly (lactide-co-glycolide) acid nanoencapsulation of a synthetic coumarin: cytotoxicity and bio-distribution in mice, in cancer cell line and interaction with calf thymus DNA as target. Toxicol Appl Pharmacol 253:270–81
   PubMed Web of Science ®Google Scholar
• Brown RC, Morris AP, O'Neil RG. (2007). Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 1130:17–30
   PubMed Web of Science ®Google Scholar
• Couvreur P, Kante B, Grislain L, et al. (1982). Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles. J Pharm Sci 71:790–2
   PubMed Web of Science ®Google Scholar
• Dietschy JM, Turley SD. (2001). Cholesterol metabolism in the brain. Curr Opin. Lipidol 12:105–12
   PubMed Web of Science ®Google Scholar
• Dong Y, Feng SS. (2005). Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:6068–76
   PubMed Web of Science ®Google Scholar
• Fan CH, Ting CY, Chang YC, et al. (2015). Drug-loaded bubbles with matched focused ultrasound excitation for concurrent blood–brain barrier opening and brain-tumor drug delivery. Acta Biomater 15:89–101
   PubMed Web of Science ®Google Scholar
• Fan CH, Yeh CK. (2014). Microbubble-enhanced focused ultrasound-induced blood–brain barrier opening for local and transient drug delivery in central nervous system disease. J Med Ultrasound 22:183–93
   Google Scholar
• Fasehee H, Dinarvand R, Ghavamzadeh A, et al. (2016). Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations. J Nanobiotechnology 14:32
   PubMed Web of Science ®Google Scholar
• Friese A, Seiller E, Quack G, et al. (2000). Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 49:103–9
   PubMed Web of Science ®Google Scholar
• Gutowski SM, Shoemaker JT, Templeman KL, et al. (2015). Protease-degradable PEG-maleimide coating with on-demand release of IL-1Ra to improve tissue response to neural electrodes. Biomaterials 44:55–70
   PubMed Web of Science ®Google Scholar
• Harris JM, Martin NE, Modi M. (2001). Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539–51
   PubMed Web of Science ®Google Scholar
• Jain D, Bajaj A, Athawale R, et al. (2016). Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies. Drug Deliv 23:999–1016
   PubMed Web of Science ®Google Scholar
• Joshi SA, Chavhan SS, Sawant KK, et al. (2010). Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 76:189–99
   PubMed Web of Science ®Google Scholar
• Kasinathan N, Jagani HV, Alex AT, et al. (2015). Strategies for drug delivery to the central nervous system by systemic route. Drug Deliv 22:243–57
   PubMed Web of Science ®Google Scholar
• Khatik R, Dwivedi P, Shukla A, et al. (2016). Development, characterization and toxicological evaluations of phospholipids complexes of curcumin for effective drug delivery in cancer chemotherapy. Drug Deliv 23:1067–78
   PubMed Web of Science ®Google Scholar
• Koffie RM, Farrar CT, Saidi LJ, et al. (2011). Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc Natl Acad Sci USA 108:18837–42
   PubMed Web of Science ®Google Scholar
• Kolate A, Baradia D, Patil S, et al. (2014). PEG – a versatile conjugating ligand for drugs and drug delivery systems. J Control Release 192:67–81
   PubMed Web of Science ®Google Scholar
• Kolter M, Ott M, Hauer C, et al. (2015). Nanotoxicity of poly(n-butylcyano-acrylate) nanoparticles at the blood–brain barrier, in human whole blood and in vivo. J Control Release 197:165–79
   PubMed Web of Science ®Google Scholar
• Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65–81
   PubMed Web of Science ®Google Scholar
• Kreuter J, Alyautdin RN, Kharkevich DA, et al. (1995). Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674:171–4
   PubMed Web of Science ®Google Scholar
• Li JW, Feng L, Fan L, et al. (2011). Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 32:4943–50
   PubMed Web of Science ®Google Scholar
• Li C, Shen Y, Sun C, et al. (2016). Immunosafety and chronic toxicity evaluation of monomethoxypoly(ethylene glycol)-b-poly(lactic acid) polymer micelles for paclitaxel delivery. Drug Deliv 23:888–95
   PubMed Web of Science ®Google Scholar
• Lin Y, Pan Y, Shi Y, et al. (2012). Delivery of large molecules via poly(butyl cyanoacrylate) nanoparticles into the injured rat brain. Nanotechnology 23:165101–8
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Z, Jiang Y, et al. (2015). Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent tamibarotene: characterization and evaluation. Drug Deliv 22:223–9
   PubMed Web of Science ®Google Scholar
• Luo YL, Miao Y, Xu F. (2011). Synthesis, phase behavior, and simulated in vitro degradation of novel HTPB-b-PEG polyurethane copolymers. Macromol Res 19:1233–41
   Web of Science ®Google Scholar
• Mahajan HS, Mahajan MS, Nerkar PP, et al. (2014). Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Drug Deliv 21:148–54
   PubMed Web of Science ®Google Scholar
• Md S, Ali M, Baboota S, et al. (2013). Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev Ind Pharm 40:278–87
   PubMed Web of Science ®Google Scholar
• Neuwelt EA, Bauer B, Fahlke C, et al. (2011). Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci 12:169–82
   PubMed Web of Science ®Google Scholar
• Olivier JC, Huertas R, Lee HJ, et al. (2002). Synthesis of pegylated immunonanoparticles. Pharm Res 19:1137–43
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2007). Drug targeting to the brain. Pharm Res 24:1733–44
   PubMed Web of Science ®Google Scholar
• Reed B, Villeneuve S, Mack W, et al. (2014). Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol 71:195–200
   PubMed Web of Science ®Google Scholar
• Stefani M, Coudane J, Vert M. (2006). In vitro ageing and degradation of PEG–PLA diblock copolymer-based nanoparticles. Polym Degrad Stabil 91:2554–9
   Web of Science ®Google Scholar
• Simsek S, Eroglu H, Kurum B, et al. (2013). Brain targeting of atorvastatin loaded amphiphilic PLGA-b-PEG nanoparticles. J Microencapsul 30:10–20
   PubMed Web of Science ®Google Scholar
• Tian XH, Lin XN, Wei F, et al. (2011). Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine 6:445–52
   PubMed Web of Science ®Google Scholar
• Ushio-Fukai M, Hilenski L, Santanam N, et al. (2013). Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: role of cholesterolrich microdomains and focal adhesions in angiotensin II signaling. J Biol Chem 276:48269–75
   Web of Science ®Google Scholar
• Xia H, Gao X, Gu G, et al. (2012). Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int J Pharm 436:840–50
   PubMed Web of Science ®Google Scholar
• Xu H, Ye F, Hu M, et al. (2015). Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection. Drug Deliv 22:598–607
   PubMed Web of Science ®Google Scholar
• Yordanova G, Skrobanskab R, Evangelatovb A. (2013). Colloidal formulations of etoposide based on poly(butyl cyanoacrylate) nanoparticles: Preparation, physicochemical properties and cytotoxicity. Colloids Surf B: Biointerfaces 101C:215–22
   Web of Science ®Google Scholar
• Zambaux MF, Bonneaux F, Gref R, et al. (2001). Protein C-loaded monomethoxypoly (ethylene oxide)–poly(lactic acid) nanoparticles. Int J Pharm 212:1–9
   PubMed Web of Science ®Google Scholar
• Zhao S, Dai W, He B, et al. (2011). Monitoring the transport of polymeric micelles across MDCK cell monolayer and exploring related mechanisms. J Control Release 158:413–23
   PubMed Web of Science ®Google Scholar
• Zhou YZ, Alany RG, Chuang V, et al. (2013). Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design. Drug Dev Ind Pharm 39:468–72
   Web of Science ®Google Scholar